Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 53% Improvement Relative Risk Ventilation 64% ICU admission 60% Death/ventilation/ICU 58% primary Progression to ARDS 85% c19zinc.com Mayberry et al. Zinc for COVID-19 EARLY TREATMENT Favors zinc Favors control
Mayberry, 2,028 patient zinc early treatment study: 53% lower mortality [p<0.0001], 64% lower ventilation [p<0.0001], 60% lower ICU admission [p<0.0001], and 58% lower combined mortality/ICU admission [p<0.0001] https://c19p.org/mayberry
copied to clipboard
Zinc use is associated with improved outcomes in COVID-19: results from the CRUSH-COVID registry
Mayberry et al., Critical Care Medicine, doi:10.1097/01.ccm.0000807104.82650.d6
16 Dec 2021    Source   PDF   Share   Tweet
Retrospective 2,028 COVID patients in the USA, showing significantly lower mortality, ventilation, ICU admission, and progression to ARDS with zinc use, defined as at least one dose from one week prior to admission to 48 hours after admission.
risk of death, 53.5% lower, OR 0.47, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
risk of mechanical ventilation, 64.2% lower, OR 0.36, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
risk of ICU admission, 60.0% lower, OR 0.40, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
death/ventilation/ICU, 57.8% lower, OR 0.42, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, primary outcome, RR approximated with OR.
progression to ARDS, 85.4% lower, OR 0.15, p < 0.001, treatment 938, control 1,090, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mayberry et al., 12/16/2021, retrospective, USA, North America, peer-reviewed, 14 authors, study period March 2020 - April 2021.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit